IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9321727 B1

PDFFull Text
Date of Patent:
Apr. 26, 2016

Filed:

Jun. 01, 2012

Pyridine derivatives as agonists of the cb2 receptor

Applicants:

Caterina Bissantz, Village-Neuf, FR;

Uwe Grether, Efringen-Kirchen, DE;

Paul Hebeisen, Basel, CH;

Atsushi Kimbara, Tokyo, JP;

Qingping Liu, Beijing, CN;

Matthias Nettekoven, Grenzach-Wyhlen, DE;

Marco Prunotto, Delémont, CH;

Stephan Roever, Inzlingen, DE;

Mark Rogers-evans, Bottmingen, CH;

Tanja Schulz-gasch, Ziefen, CH;

Christoph Ullmer, Fischingen, DE;

Zhiwei Wang, Beijing, CN;

Wulun Yang, Beijing, CN;

Inventors:

Caterina Bissantz, Village-Neuf, FR;

Uwe Grether, Efringen-Kirchen, DE;

Paul Hebeisen, Basel, CH;

Atsushi Kimbara, Tokyo, JP;

Qingping Liu, Beijing, CN;

Matthias Nettekoven, Grenzach-Wyhlen, DE;

Marco Prunotto, Delémont, CH;

Stephan Roever, Inzlingen, DE;

Mark Rogers-Evans, Bottmingen, CH;

Tanja Schulz-Gasch, Ziefen, CH;

Christoph Ullmer, Fischingen, DE;

Zhiwei Wang, Beijing, CN;

Wulun Yang, Beijing, CN;

Assignee:

Hoffmann-La Roche Inc., Nutley, NJ (US);

Attorney:
Primary Examiner:

Rita Desai

Assistant Examiner:

Ben S Michelson

Int. Cl.
CPC ...
C07D 211/68 (2006.01); C07D 211/80 (2006.01); C07D 213/02 (2006.01); C07D 401/00 (2006.01); C07D 419/00 (2006.01); C07D 417/00 (2006.01); C07D 405/00 (2006.01); C07D 213/62 (2006.01); C07D 213/78 (2006.01); C07D 211/78 (2006.01); C07D 211/90 (2006.01); C07D 213/81 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/06 (2006.01); C07D 417/12 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
C07D 213/81 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 417/12 (2013.01); C07D 491/107 (2013.01);
Abstract

The invention relates to a compound of formula (I) Wherein R, R, Rand Rare defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.

Find Patent Forward Citations

Loading…